Drug Profile
Lazertinib - Janssen Biotech/Yuhan
Alternative Names: C-18112003-G; GNS 1480; JNJ 73841937; JNJ-1937; JNJ-73841937-AAA; Lazertinib mesylate monohydrate; Leclaza; YH-25448Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Oscotec
- Developer Janssen Biotech; Janssen Research & Development; Memorial Sloan-Kettering Cancer Center; Yuhan
- Class Amides; Aniline compounds; Antineoplastics; Dimethylamines; Ethers; Morpholines; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 31 Dec 2023 Preregistration for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in European Union (PO) in Q4 2023
- 23 Oct 2023 Efficacy and adverse event data from a Phase III clinical trials in Non-small cell lung cancer released by Janssen
- 20 Oct 2023 Updated efficacy data from the phase III MARIPOSA trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)